Clorox Q4 And FY26 Profit Declines

Clorox (CLX) reported lower Q4 and FY2026 profit, citing year-over-year sales declines. The company posted non-GAAP EPS of $1.66 for the quarter, slightly above estimates, and revenue of $1.95B, above expectations, according to the article.

Original reporting
Published Aug 3, 2026, 11:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 11:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CLX
Bearish
medium confidence
Mentioned
$CLX
Relevance
7/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$CLXBearishMed
01

Why it matters

Lower profit alongside declining sales typically leads traders to reassess forward earnings estimates, margin outlook, and demand durability for the household products segment.

02

Market read

This is a direct earnings datapoint for CLX, relevant for positioning around consumer staples demand and profitability expectations.

03

What to watch

The excerpt is truncated; traders should verify guidance, margin drivers, and any commentary on cost actions or category demand before extrapolating the profit decline into a sustained downtrend.

Relevance 7/10Novelty 6/10Timing: reported Monday after the close or pre-market (article timestamp 2026-08-03 23:15 UTC)

Background

The piece is a summary of Clorox’s reported lower Q4 and full-year fiscal 2026 earnings, with sales down year over year.

Company-level read

Ticker impact

$CLXBearishMedium confidence
Context

Clorox reported lower Q4 and FY26 profit as sales declined versus the prior year, making the earnings print the direct driver for CLX risk and positioning.

Expected impact

Near-term downside bias with elevated volatility around earnings follow-through, unless management commentary offsets the profit decline.

Evidence & confidence

The article explicitly states lower fourth-quarter and full-year fiscal 2026 profit tied to declining sales, which typically drives negative sentiment and re-pricing of forward earnings power.

Market effects

Signals continued pressure in consumer staples demand and/or pricing/mix for household products, which can weigh on peers’ near-term sentiment.

No clear regional transmission beyond US-listed consumer staples sentiment.

Limited global spillover indicated; this is company-specific earnings information.

Counterpoint

If the profit decline is driven by temporary cost timing or one-offs, the stock reaction could be muted once management details normalize the underlying trend.

Key entities

  • The Clorox Company

    Subject of the article, reporting lower Q4 and FY26 profit as sales declined year over year.

Related articles

$CLXMed

The Clorox Company Q4 2026 Earnings Call Summary

Clorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.

$CLXMedAI 8/10

Clorox fiscal 2027 outlook: inflation and value shoppers weigh

Clorox forecast a difficult fiscal 2027, citing inflation and consumers shifting to value. The company expects net sales up 13% to 14% for fiscal 2027, with about 9.5 points from its April 2026 GOJO Industries acquisition. Adjusted EPS is projected at $5.70 to $6.00, GAAP diluted EPS $5.41 to $5.71. Q4 revenue fell 2% to $1.95B; adjusted EPS was $1.66.

$CLXMedAI 8/10

Clorox forecasts upbeat annual sales as demand improves

Reuters reports Clorox (Pine-Sol maker) forecast fiscal 2027 net sales growth of 13% to 14%, above analysts’ 12.8% estimate, and adjusted EPS of $5.70 to $6 versus $5.97 expected. Q4 sales fell 2% to $1.95B but beat $1.90B. Gross margin dropped to 41.3%. Clorox cited improving demand amid a challenging cost and value-seeking environment.

$CLXMedAI 8/10

CLOROX CO /DE/ (CLX): Results of Operations and Financial Condition

CLOROX CO /DE/ (CLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-pressreleasedatedaug.htm EX-99.1 Document Clorox Reports Q4 and FY26 Results, Provides FY27 Outlook Delivers Q4 results in line with expectations while advancing strategic investments OAKLAND, California, Aug. 3, 2026 — The Clorox Company (NYSE: CLX) today reporte

$CLXMedAI 9/10

Clorox Announces Leadership Transition as CEO Linda Rendle Prepares to Exit

The Wall Street Journal reported May 28 that Clorox CEO Linda Rendle will step down for health reasons after more than two decades. Clorox said it has started a comprehensive search for a new chief executive, while Rendle will remain in her role. In a blog post, Rendle said she was diagnosed with early-stage breast cancer, is now cancer-free, and cited ongoing treatment side effects.

$KMBLow

Kimberly-Clark vs. The Clorox: Which Consumer Goods Stock Is a Better Buy in 2026?

The article compares Kimberly-Clark (KMB) and The Clorox Company (CLX) as consumer staples for 2026. Kimberly-Clark reported FY2025 revenue near $16.4B (down from $16.8B) and net income about $2.0B; Clorox reported FY2025 revenue near $7.1B (flat) and net income about $810M. It cites higher customer concentration for both (Walmart ~16% for KMB, ~27% for Clorox) and notes KMB is selling tissue operations to Suzano and has a potential $48B merger with Kenvue, while Clorox is recovering from a 2023